Company profile

Ticker
BMRA
Exchange
CEO
Zackary S. Irani
Employees
Incorporated in
Location
Fiscal year end
Former names
NMS PHARMACEUTICALS INC, NUCLEAR MEDICAL SYSTEMS INC, NUCLEAR INSTRUMENTS INC
SEC CIK
IRS number
952645573

BMRA stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

14 Apr 20
4 Jul 20
31 May 21

News

Company financial data Financial data

Quarter (USD) Feb 20 Nov 19 Aug 19 May 19
Revenue 1.18M 1.6M 1.19M 1.17M
Net income -860.93K -485.26K -506.3K -785.33K
Diluted EPS -0.09 -0.05 -0.05 -0.08
Net profit margin -73.15% -30.40% -42.39% -67.36%
Operating income -914.89K -489.74K -509.56K -764.82K
Net change in cash 1.54M 43.44K 120.77K -231.15K
Cash on hand 2.39M 850.99K 807.55K 686.79K
Cost of revenue 964.91K 1.13M 827.11K 985.05K
Annual (USD) May 19 May 18 May 17 May 16
Revenue 5.2M 5.56M 5.79M 5.14M
Net income -2.39M -1.47M -908.56K -1.5M
Diluted EPS -0.26 -0.17 -0.11 -0.2
Net profit margin -46.01% -26.34% -15.69% -29.18%
Operating income -2.41M -1.48M -954.63K -826.95K
Net change in cash -518.12K -20.56K -663.46K 800.62K
Cash on hand 686.79K 1.2M 1.23M 1.89M
Cost of revenue 3.91M 3.81M 3.77M 3.62M

Financial data from Biomerica earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
21 Apr 20 Sirgo Mark A Common Stock Sell Dispose S No 8.1063 5,000 40.53K 8,700
17 Apr 20 Sirgo Mark A Common Stock Sell Dispose S No 8.077 2,454 19.82K 13,700
17 Apr 20 Sirgo Mark A Common Stock Sell Dispose S No 8.07 1,302 10.51K 16,154
17 Apr 20 Sirgo Mark A Common Stock Sell Dispose S No 8.05 1,076 8.66K 17,456
17 Apr 20 Sirgo Mark A Common Stock Sell Dispose S No 8.06 100 806 18,532
17 Apr 20 Sirgo Mark A Common Stock Sell Dispose S No 8.09 68 550.12 18,632
1 Apr 20 Barbieri Allen Common Stock Gift Dispose G No 0 23,000 0 137,289
28 Feb 20 Zackary S. Irani Common Stock Other Aquire J No 2.85 78,431 223.53K 1,002,160
2 Jan 20 Janet Moore Common Stock Gift Dispose G No 0 20,000 0 101,720
19 Dec 19 Zackary S. Irani Non Qualified Stock Option Common Stock Grant Aquire A No 2.81 125,000 351.25K 555,000
4.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 22 11 +100.0%
Opened positions 13 1 +1200.0%
Closed positions 2 1 +100.0%
Increased positions 5 2 +150.0%
Reduced positions 2 1 +100.0%
13F shares
Current Prev Q Change
Total value 3.85M 704K +446.6%
Total shares 513.29K 235.08K +118.3%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Vanguard 293.79K $2.1M +132.8%
Geode Capital Management 49.33K $352K NEW
Heritage Investors Management 38.15K $273K +145.3%
Perritt Capital Management 30K $215K -53.8%
Millennium Management 26.22K $187K NEW
Creative Planning 17K $122K NEW
MS Morgan Stanley 16.04K $115K NEW
GS The Goldman Sachs Group, Inc. 10.54K $75K NEW
Bard Associates 10K $72K 0.0%
WFC Wells Fargo & Co. 7.95K $56K +22.3%
Largest transactions
Shares Bought/sold Change
Vanguard 293.79K +167.57K +132.8%
Geode Capital Management 49.33K +49.33K NEW
Perritt Capital Management 30K -35K -53.8%
Millennium Management 26.22K +26.22K NEW
Heritage Investors Management 38.15K +22.6K +145.3%
Creative Planning 17K +17K NEW
MS Morgan Stanley 16.04K +16.04K NEW
GS The Goldman Sachs Group, Inc. 10.54K +10.54K NEW
WFC Wells Fargo & Co. 7.95K +1.45K +22.3%
UBS UBS 1.14K +1.14K NEW

Financial report summary

?
Management Discussion
  •      Consolidated net sales for Biomerica were $1,176,889 for the three months ended February 29, 2020 as compared to $1,261,161 for the three-month period ended February 28, 2019. This represents a decrease of $84,272 or 6.7%. For the nine-month period ended February 29, 2020 as compared to the nine-month period ended February 28, 2019, net sales were $3,967,712 as compared to $4,034,822.  This represents a decrease of $67,110 or 1.7%. The decrease for the three-month period and for the nine-month period was primarily due to lower sales to China as a result of the coronavirus in China during the quarter ended February 29, 2020.
  •      For the three months ended February 29, 2020 as compared to the three months ended February 28, 2019, cost of sales increased as a percentage of sales from 71.0% of sales, or $895,237, to 82.0% of sales, or $964,910.  For the nine months ended February 29, 2020 as compared to February 28, 2019, cost of sales as a percentage of sales increased from 72.5% of sales, or $2,923,615 to 73.6% of sales, or $2,919,557. The increase to cost of goods as a percentage of sales for the three and nine months were due to increased material costs, higher wages and benefits’ costs as well as fixed costs in relation to lower sales during the quarter and nine months ended February 29, 2020.
  •      For the three months ended February 29, 2020 compared to February 28, 2019, selling, general and administrative expenses increased by $77,515, or 13.5%. For the nine months ended February 29, 2020 as compared to February 28, 2019, selling, general and administrative expenses increased by $225,653, or 15.2%. The increase for the quarter and nine months ended February 29, 2020 as compared to February 28, 2019, was primarily due to an increase of non-cash option expense, and increased wages and consulting fees.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: absenteeism, accurate, aimed, alternative, anniversary, ATM, Authorization, avoid, begun, breakdown, broker, Cap, carefully, case, CEO, chain, closure, complimentary, confirmed, consecutive, consent, conversion, convert, converted, convertible, decision, demonstrate, depend, depression, directed, Disaggregation, dissolution, efficacy, eligible, ELISA, Emergency, entitled, equal, error, eventual, exempt, EXTENSIVE, face, fall, finger, format, found, gain, Gaining, global, holder, home, Hubei, Icahn, IgG, IgM, ii, implement, implemented, ineffective, infection, inoperable, insolvency, integrate, laboratory, license, licensed, liquidation, logistical, LP, marketplace, Master, Medicine, microplate, million, Mount, negotiated, outbreak, Palm, pandemic, participating, partner, PCR, preferred, prick, prohibit, promising, proposed, Province, qualitative, Rapid, recession, refuse, render, resale, risk, royalty, run, safe, scale, School, serological, serum, shelter, show, Sinai, SOCIETAL, speed, spread, spreading, subscribed, subscription, sufficiently, system, thereon, thereunder, trained, transaction, travel, treating, Ultimately, unable, unaware, unforeseen, unpaid, validate, version, view, volume, widespread, winding, world, Wuhan, York
Removed: abroad, alleging, anticipate, arise, border, brought, carried, climate, competition, competitive, complying, concentrated, counter, degradation, desired, difficulty, discussed, disruption, enactment, escalation, Europe, exhaustive, expansion, fluctuate, foreseeable, gastroenterology, high, highlight, hire, imposed, inability, incorporated, key, labor, lead, macroeconomic, manage, meant, mix, negative, obtain, obtaining, occasion, October, operate, paying, performance, predict, previously, profitability, protracted, receiving, reduced, reference, response, shutdown, significantly, spending, subject, substantially, support, terrorist, unpredictably